Monica Gandhi, MD, MPH

Headshot of Monica Gandhi
User Profile Photo

Monica Gandhi, MD, MPH

User Profile Name
Director, UCSF-Bay Area CFAR
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Dr. Gandhi has been at UCSF since 1996 when she came here for her medical residency after attending Harvard Medical School. She completed an ID fellowship at UCSF from 1999-2003 and a Masters’ in Public Health in Epidemiology/Biostatistics from the University of California, Berkeley in 2001, as well as a Traineeship in AIDS Prevention Studies (TAPS) post-doctoral fellowship. She has been an NIH funded researcher since 2003, first with a K23 award and now with multiple R01 and R21 grants to help run the UCSF Hair Analytical Laboratory (HAL), a laboratory that focuses on objective adherence metrics to HIV treatment and prevention for multiple UCSF-based and global investigators in hair and urine. She served on the Office of AIDS Research Advisory Committee (OARAC) from 2014-2017 and Chair from 2017-2018. She also serves on the ACTG Executive Committee. She has served as the co-director of the CFAR Mentoring Program for the past five years and has a dedicated interest in HIV mentorship and education.

Dr. Gandhi serves as the Medical Director of the Ward 86 HIV Clinic (since January 2014) and won the HIV Medical Association (HIVMA) Clinical Educator Award in 2017 and was awarded the Master Clinician award in the Department of Medicine in 2019. Beyond an interest in adherence metrics and PrEP, Dr. Gandhi has a special interest in HIV and women and sex differences in HIV medicine. She is thrilled to serve in this role to support the HIV/AIDS researcher community across UCSF and our many affiliates. She is especially interested in mentoring early stage investigators, especially those from underrepresented racial/ethnic minorities, from disadvantaged backgrounds, and with disabilities. Monica plans an open door policy with the CFAR community here at UCSF and is excited to serve with you all in continuing to make UCSF an innovative and exciting place to conduct HIV research.

User Profile Bio

Displaying 26 - 50 of 291

  1. Conroy AA, McKenna S, Ruark A, Neilands TB, Spinelli M, Gandhi M. Relationship Dynamics are Associated with Self-Reported Adherence but not an Objective Adherence Measure in Malawi. AIDS Behav. 2022 Nov; 26(11):3551-3562.
  2. Greene M, Shi Y, Boscardin J, Sudore R, Gandhi M, Covinsky K. Geriatric conditions and healthcare utilisation in older adults living with HIV. Age Ageing. 2022 05 01; 51(5).
  3. Qasmieh S, Nash D, Gandhi M, Rozen E, Okochi H, Goldstein H, Herold BC, Jamison K, Pathela P. Self-Reported Use of HIV Preexposure Prophylaxis Is Highly Accurate Among Sexual Health Clinic Patients in New York City. Sex Transm Dis. 2022 11 01; 49(11):790-793.
  4. Murnane PM, Gandhi M, Bacchetti P, Getahun M, Gutin SA, Okochi H, Maeri I, Eyul P, Omoding D, Okiring J, Tallerico R, Louie A, Akullian A, Kamya MR, Bukusi EA, Charlebois ED, Camlin CS. Distinct forms of migration and mobility are differentially associated with HIV treatment adherence. AIDS. 2022 06 01; 36(7):1021-1030.
  5. Hojilla JC, Gandhi M, Satre DD, Johnson MO, Saberi P. Equity in access to long-acting injectables in the USA. Lancet HIV. 2022 03; 9(3):e145-e147.
  6. Jennings L, Kellermann T, Spinelli M, Nkantsu Z, Cogill D, van Schalkwyk M, Decloedt E, van Zyl G, Orrell C, Gandhi M. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS Res Hum Retroviruses. 2022 06; 38(6):455-462.
  7. Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, Durstenfeld MS, Spinelli MA, Hoh R, Tai V, Fehrman EA, Torres L, Hernandez Y, Williams MC, Arreguin MI, Ngo LH, Deswal M, Munter SE, Martinez EO, Anglin KA, Romero MD, Tavs J, Rugart PR, Chen JY, Sans HM, Murray VW, Ellis PK, Donohue KC, Massachi JA, Weiss JO, Mehdi I, Pineda-Ramirez J, Tang AF, Wenger MA, Assenzio MT, Yuan Y, Krone MR, Rutishauser RL, Rodriguez-Barraquer I, Greenhouse B, Sauceda JA, Gandhi M, Scheffler AW, Hsue PY, Henrich TJ, Deeks SG, Martin JN. Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infect Dis. 2022 Feb; 9(2):ofab640.
  8. Santiago-Rodriguez EI, Maiorana A, Peluso MJ, Hoh R, Tai V, Fehrman EA, Hernandez Y, Torres L, Spinelli MA, Gandhi M, Kelly JD, Martin JN, Henrich TJ, Deeks SG, Sauceda JA. Characterizing the COVID-19 Illness Experience to Inform the Study of Post-acute Sequelae and Recovery. Int J Behav Med. 2022 Oct; 29(5):610-623.
  9. Ekstrand ML, Heylen E, Gandhi M, Steward WT, Pereira M, Srinivasan K. COVID-19 Vaccine Hesitancy Among PLWH in South India: Implications for Vaccination Campaigns. J Acquir Immune Defic Syndr. 2021 12 15; 88(5):421-425.
  10. Murnane PM, Ayieko J, Vittinghoff E, Gandhi M, Katumbi C, Milala B, Nakaye C, Kanda P, Moodley D, Nyati ME, Loftis AJ, Fowler MG, Flynn P, Currier JS, Cohen CR. Machine learning algorithms using routinely collected data do not adequately predict viremia to inform targeted services in postpartum women living with HIV. J Acquir Immune Defic Syndr. 2021 Sep 14.
  11. Matthew A Spinelli, Michael J Peluso, Kara Lynch, Cassandra Yun, David V Glidden, Timothy J Henrich, Steve Deeks, Monica Gandhi. LB8. Lower SARS-CoV-2 IgG and Pseudovirus Neutralization Titers Post-mRNA Vaccination among People Living with HIV. Open Forum Infectious Diseases. 2021 Dec 4; 8(Suppl 1):s805-s805.
  12. Spinelli MA, Brown LB, Glidden DV, Hunter K, Martin-Tuite P, Zheng J, Sera C, Havlir D, Buchbinder SP, Gandhi M. SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV. AIDS. 2021 12 01; 35(15):2545-2547.
  13. Halperin DT, Hearst N, Hodgins S, Bailey RC, Klausner JD, Jackson H, Wamai RG, Ladapo JA, Over M, Baral S, Escandón K, Gandhi M. Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here. BMC Public Health. 2021 11 13; 21(1):2084.
  14. Tan JY, Greene M, Blat C, Albers A, Grochowski J, Oskarsson J, Shiels M, Hsue P, Havlir D, Gandhi M, Myers J. Examining the Impact of the Golden Compass Clinical Care Program for Older People with HIV: A Qualitative Study. AIDS Behav. 2022 May; 26(5):1562-1571.
  15. Johnson MO, Gandhi M, Fuchs JD, Sterling L, Sauceda JA, Saag MS, Riley ED, Sevelius JM. The impact of COVID-19 on mentoring early-career investigators: "Everything can wait. Listen more than usual and share your own struggles". Medicine (Baltimore). 2021 Oct 08; 100(40):e27423.
  16. Bardon AR, Dorward J, Sookrajh Y, Sayed F, Quame-Amaglo J, Pillay C, Feutz E, Ngobese H, Simoni JM, Sharma M, Cressey TR, Gandhi M, Lessells R, Moodley P, Naicker N, Naidoo K, Thomas K, Celum C, Abdool Karim S, Garrett N, Drain PK. Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes. BMJ Open. 2021 10 05; 11(10):e050116.
  17. Nwogu JN, Gandhi M, Owen A, Khoo SH, Taiwo B, Olagunju A, Berzins B, Okochi H, Tallerico R, Robertson K, Babalola CP. Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. AIDS. 2021 10 01; 35(12):1919-1927.
  18. Chawana TD, Nhachi CFB, Nathoo K, Ngara B, Okochi H, Louie A, Kuncze K, Katzenstein D, Metcalfe J, Gandhi M, Adolescent Treatment Failure (ATF) Study Team. Brief Report: Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment. J Acquir Immune Defic Syndr. 2021 10 01; 88(2):181-185.
  19. Christopoulos KA, Erguera XA, VanderZanden L, Campbell C, Green M, Tsuzuki MD, Schneider J, Coffey S, Bacon O, Gandhi M, Koester KA. A Qualitative Study of the Experience of Immediate Antiretroviral Therapy Among Urban Persons With Newly Diagnosed Human Immunodeficiency Virus. Open Forum Infect Dis. 2021 Dec; 8(12):ofab469.
  20. Johnson KA, Okochi H, Glidden DV, Gandhi M, Spinelli M. Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide. J Acquir Immune Defic Syndr. 2021 09 01; 88(1):57-60.
  21. Salinas-Rodríguez A, Sosa-Rubí SG, Chivardi C, Rodríguez-Franco R, Gandhi M, Mayer KH, Operario D, Gras-Allain N, Vargas-Guadarrama G, Galárraga O. Preferences for Conditional Economic Incentives to Improve Pre-exposure Prophylaxis Adherence: A Discrete Choice Experiment Among Male Sex Workers in Mexico. AIDS Behav. 2022 Mar; 26(3):833-842.
  22. Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman EA, Spinelli MA, Gandhi M, Trinh L, Wrin T, Petropoulos CJ, Aweeka FT, Rodriguez-Barraquer I, Kelly JD, Martin JN, Deeks SG, Greenhouse B, Rutishauser RL, Henrich TJ. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021 08 10; 36(6):109518.
  23. Spinelli MA, Glidden DV, Gennatas ED, Rutherford GW, Gandhi M. Effectiveness of Adding a Mask Recommendation to Other Public Health Measures. Ann Intern Med. 2021 08; 174(8):1193.
  24. Chamie G, Marquez C, Crawford E, Peng J, Petersen M, Schwab D, Schwab J, Martinez J, Jones D, Black D, Gandhi M, Kerkhoff AD, Jain V, Sergi F, Jacobo J, Rojas S, Tulier-Laiwa V, Gallardo-Brown T, Appa A, Chiu C, Rodgers M, Hackett J, CLIAhub Consortium , Kistler A, Hao S, Kamm J, Dynerman D, Batson J, Greenhouse B, DeRisi J, Havlir DV. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the Latinx Population During Shelter-in-Place in San Francisco. Clin Infect Dis. 2021 07 30; 73(Suppl 2):S127-S135.
  25. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Donatelli J, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox MA, Vallari A, Rodgers MA, Prostko J, Hackett J, Trinh L, Wrin T, Petropoulos CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv. 2021 Jul; 7(31).